Neoadjuvant chemoradiotherapy (nCRT) improves outcomes in resectable esophageal adenocarcinoma (EAC), but acquired resistance precludes long-term efficacy. Here, we delineate these resistance mechanisms. RNA sequencing on matched patient samples obtained pre-and post-neoadjuvant treatment reveal that oxidative phosphorylation was the most upregulated of all biological programs following nCRT. Analysis of patient-derived models confirms that mitochondrial content and oxygen consumption strongly increase in response to nCRT and that ionizing radiation is the causative agent. Bioinformatics identifies estrogen-related receptor alpha (ESRRA) as the transcription factor responsible for reprogramming, and overexpression and silencing of ESRRA functionally confirm that its downstream metabolic rewiring contributes to resistance. Pharmacological inhibition of ESRRA successfully sensitizes EAC organoids and patient-derived xenografts to radiation. In conclusion, we report a profound metabolic rewiring following chemoradiation and demonstrate that its inhibition resensitizes EAC cells to radiation. These findings hold broader relevance for other cancer types treated with radiation as well.
Authors
Mark P.G. Dings, Amber P. van der Zalm, Sanne Bootsma, Tatum F.J. van Maanen, Cynthia Waasrop, Tom van den Ende, Daija Liu, Peter Bailey, Jan Koster, Danny A. Zwijnenburg, C. Arnold Spek, Jan P.G. Klomp, Arthur Oubrie, Gerrit K.J. Hooijer, Sybren L. Meijer, Mark I. van Berge Henegouwen, Maarten C. Hulshof, Jacques Bergman, Cesar Oyarce, Jan Paul Medema, Hanneke W.M. van Laarhoven, Maarten F. Bijlsma.